دورية أكاديمية
أعرض في EDS

TWEAK levels in psoriatic patients treated with narrowband ultraviolet B and methotrexate.

التفاصيل البيبلوغرافية
العنوان: TWEAK levels in psoriatic patients treated with narrowband ultraviolet B and methotrexate.
المؤلفون: Hegazy EM; Dermatology, Venereology, and Andrology Department, Faculty of Medicine, South Valley University, Qena, Egypt., El Taieb MA; Dermatology, Venerology, and Andrology Department, Faculty of Medicine, Aswan University, Aswan, Egypt., Ibrahim HM; Dermatology, Venereology, and Andrology Department, Faculty of Medicine, South Valley University, Qena, Egypt., Rageh EM; Dermatology, Venerology, and Andrology Department, Faculty of Medicine, Aswan University, Aswan, Egypt., Ahmed NM; Clinical Pathology Department, Faculty of Medicine, Aswan University, Aswan, Egypt., Ibrahim AK; Department of Public Health, Faculty of Medicine, Assiut University, Asyut, Jordan.; Basic Medical Science Department, Faculty of Medicine, Aqaba Medical Sciences University, Aqaba, Jordan., Younis AM; Dermatology, Venerology, and Andrology Department, Faculty of Medicine, Aswan University, Aswan, Egypt., Ali MA; Dermatology, Venerology, and Andrology Department, Faculty of Medicine, Aswan University, Aswan, Egypt.
المصدر: Journal of cosmetic dermatology [J Cosmet Dermatol] 2024 May; Vol. 23 (5), pp. 1905-1911. Date of Electronic Publication: 2024 Feb 01.
نوع المنشور: Journal Article; Randomized Controlled Trial
اللغة: English
بيانات الدورية: Publisher: Blackwell Science Country of Publication: England NLM ID: 101130964 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-2165 (Electronic) Linking ISSN: 14732130 NLM ISO Abbreviation: J Cosmet Dermatol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford, UK : Blackwell Science, c2002-
مواضيع طبية MeSH: Psoriasis*/blood , Psoriasis*/radiotherapy , Psoriasis*/therapy , Psoriasis*/drug therapy , Psoriasis*/diagnosis , Cytokine TWEAK*/blood , Methotrexate*/administration & dosage , Methotrexate*/therapeutic use , Ultraviolet Therapy*/methods, Humans ; Female ; Male ; Adult ; Middle Aged ; Combined Modality Therapy ; Dermatologic Agents/therapeutic use ; Dermatologic Agents/administration & dosage ; Severity of Illness Index ; Treatment Outcome ; Young Adult
مستخلص: Background: Psoriasis is an autoimmune disease which has an effect on the joints and skin. Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK) is a multi-functional cytokine which regulates the cellular processes and has been related to a variation of conditions.
Objectives: To measure the level of serum TWEAK in psoriatic diseased persons and its relationship to the PASI score pre- and post-therapy with narrowband ultraviolet B phototherapy (NB-UVB) and methotrexate (MTX).
Methods: This randomized controlled trial was conducted on 40 patients and 20 healthy persons as controls. Patient Group was randomly subdivided to two groups. The 1st group consisted of 20 patients who received NB-UVB treatment. The 2nd group included 20 MTX-treated candidates. Blood samples were drawn from patients in order to detect serum TWEAK levels using ELISA. The research was registered on Clinical Trials Registration: RCT approval numbers: NCT0481191.
Results: The mean PASI score percent improvement after 12 weeks of treatment was higher in the MTX group (90%) than NB-UVB group (60%). The serum TWEAK level at baseline was 60.47 ± 12.6 pg/mL in NB-UVB group and 54.69 ± 21.7 pg/mL in MTX group which reduced to 24.93 ± 17.6 pg/mL and 32.13 ± 23.6 pg/mL, respectively (p < 0.001), after 12 weeks of treatment. There was a positive correlation between the serum levels of TWEAK and severity of PASI score (r = 0.399, p = 0.014).
Conclusion: TWEAK grades in psoriasis are substantially higher than in controls. TWEAK levels were dramatically reduced during NB-UVB and MTX treatment. TWEAK may have a potential sign for psoriasis diagnosis and prognosis.
(© 2024 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.)
References: Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.
Bilgiç Ö, Sivrikaya A, Toker A, Ünlü A, Altınyazar C. Serum levels of TWEAK in patients with psoriasis vulgaris. Cytokine. 2016;77:10‐13.
Wang H, Wang S, Li L, et al. Involvement of the cytokine TWEAK in the pathogenesis of psoriasis vulgaris, pustular psoriasis, and erythrodermic psoriasis. Cytokine. 2021;138:155391.
Liu Q, Xiao S, Xia Y. TWEAK/Fn14 activation participates in skin inflammation. Mediators Inflamm. 2017;2017:6746870.
Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013;87(9):626‐633.
Toprak AE, Ozlu E, Ustunbas TK, Yalcınkaya E, Sogut S, Karadag AS. Neutrophil/lymphocyte ratio, serum endocan, and nesfatin‐1 levels in patients with psoriasis vulgaris undergoing phototherapy treatment. Med Sci Monit. 2016;22:1232‐1237.
Khafagy NH, Fathy G, Khafagy AH, Mostafa MS, Mostafa EM. Level of serum soluble endothelial leukocyte adhesion molecule‐1 in psoriatic patients after narrow‐band ultraviolet‐B and relation to disease activity: a case–control study. Egypt J Dermatol Venerol. 2017;37(1):11.
Bajaj S, Gautam RK, Khurana A, Arora P, Sharma N. Effect of narrow band ultraviolet B phototherapy on T helper 17 cell specific cytokines (interleukins‐17, 22 and 23) in psoriasis vulgaris. J Dermatol Treat. 2017;28(1):14‐17.
Myśliwiec H, Kiluk P, Myśliwiec P, Żelazowska‐Rutkowska B, Baran A, Flisiak I. Influence of narrowband ultraviolet B phototherapy on serum tumour necrosis factor‐like weak inducer of apoptosis (TWEAK) in patients with psoriasis. Clin Exp Dermatol. 2017;42(7):786‐790.
El‐esawy FM, Salem RM, Elsayed IA, El‐fallah AA, Farag MA. Factors affecting response to psoriasis treatment. Benha J Appl Sci. 2021;6(3):183‐186.
Elango T, Thirupathi A, Subramanian S, Dayalan H, Gnanaraj P. Methotrexate normalized keratinocyte activation cycle by overturning abnormal keratins as well as deregulated inflammatory mediators in psoriatic patients. Clin Chim Acta. 2015;451:329‐337.
Furiati SC, Catarino JS, Silva MV, et al. Th1, Th17, and treg responses are differently modulated by TNF‐α inhibitors and methotrexate in psoriasis patients. Sci Rep. 2019;9(1):1‐11.
Yan BX, Chen XY, Ye LR, Chen JQ, Zheng M, Man XY. Cutaneous and systemic psoriasis: classifications and classification for the distinction. Front Med. 2021;8:1820.
Chiricozzi A, Romanelli P, Volpe E, Borsellino G, Romanelli M. Scanning the immunopathogenesis of psoriasis. Int J Mol Sci. 2018;19(1):179.
Sernicola A, Russo I, Silic‐Benussi M, Ciminale V, Alaibac M. Targeting the cutaneous lymphocyte antigen (CLA) in inflammatory and neoplastic skin conditions. Expert Opin Biol Ther. 2020;20(3):275‐282.
Gupta RK, Gracias DT, Figueroa DS, et al. TWEAK functions with TNF and IL‐17 on keratinocytes and is a potential target for psoriasis therapy. Sci Immunol. 2021;6(65):eabi8823.
Bakry O, El Farargy S, Ghanayem N, Galal S. Serum omentin‐1 in psoriasis. Indian J Dermatol. 2018;63(1):85‐87.
Amer AM, Saad SM, Shalaby SM, Samir MA. Serum levels of tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) in patients with psoriasis vulgaris. Egypt J Hosp Med. 2020;81(4):1840‐1844. doi:10.21608/ejhm.2020.121009.
Nada HR, Rashed LA, Mohamed AM, Abdelkader HA. Tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) in psoriasis and atopic dermatitis: a case‐control study. J Am Acad Dermatol. 2021;84(6):1707‐1708.
Johnson‐Huang LM, Suárez‐Farinas M, Sullivan‐Whalen M, Gilleaudeau P, Krueger JG, Lowes MA. Effective narrow‐band UVB radiation therapy suppresses the IL‐23/IL‐17 axis in normalized psoriasis plaques. J Invest Dermatol. 2010;130(11):2654‐2663.
Coimbra S, Oliveira H, Reis F, et al. Interleukin (IL)‐22, IL‐17, IL‐23, IL‐8, vascular endothelial growth factor and tumour necrosis factor‐α levels in patients with psoriasis before, during and after psoralen–ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010;163(6):1282‐1290.
Elango T, Jeyaraj A, Dayalan H, Gnanaraj P, Li X, Zhang X. Immunomodulatory effect of methotrexate abruptly controls keratinocyte activation in psoriasis. In: Aghaei APS, ed. Psoriasis. IntechOpen; 2022. doi:10.5772/intechopen.102811.
Chen T, Guo ZP, Li L, et al. TWEAK enhances E‐selectin and ICAM‐1 expression, and may contribute to the development of cutaneous vasculitis. PLoS One. 2013;8(2):e56830.
Wang A, Zhang F, Xu H, et al. TWEAK/Fn14 promotes pro‐inflammatory cytokine secretion in hepatic stellate cells via NF‐κB/STAT3 pathways. Mol Immunol. 2017;87:67‐75.
Gupta RK, Gracias DT, Burkly LC, Croft M. Tumor necrosis factor like weak inducer of apoptosis (TWEAK) promotes inflammatory activity in keratinocytes with IL‐17 and TNF to drive psoriasis. J Allergy Clin Immunol. 2011;127(1):200‐207.e1–10.
Martínez‐Ramos S, Rafael‐Vidal C, Pego‐Reigosa JM, García S. Monocytes and macrophages in spondyloarthritis: functional roles and effects of current therapies. Cell. 2022;11(3):515.
فهرسة مساهمة: Keywords: NB‐UVB; TWEAK; methotrexate; psoriasis
المشرفين على المادة: 0 (Cytokine TWEAK)
YL5FZ2Y5U1 (Methotrexate)
0 (TNFSF12 protein, human)
0 (Dermatologic Agents)
تواريخ الأحداث: Date Created: 20240201 Date Completed: 20240424 Latest Revision: 20240502
رمز التحديث: 20240503
DOI: 10.1111/jocd.16215
PMID: 38299446
قاعدة البيانات: MEDLINE
الوصف
تدمد:1473-2165
DOI:10.1111/jocd.16215